The Prevention of COVID-19 in High-Risk Patients Using Tixagevimab–Cilgavimab (Evusheld): Real-World Experience at a Large Academic Center

BACKGROUND: Coronavirus disease 2019 (COVID-19) is associated with increased morbidity and mortality among immunocompromised patients. Tixagevimab–cilgavimab (Tix-Cil) is a combination of 2 monoclonal antibodies approved for the prevention of COVID-19 complications in this high-risk group. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Obaidi, Mohanad M., Gungor, Ahmet B., Kurtin, Sandra E., Mathias, Ann E., Tanriover, Bekir, Zangeneh, Tirdad T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2023
Materias:
Clinical Research Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519524/
https://www.ncbi.nlm.nih.gov/pubmed/36181789
http://dx.doi.org/10.1016/j.amjmed.2022.08.019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519524/
https://www.ncbi.nlm.nih.gov/pubmed/36181789
http://dx.doi.org/10.1016/j.amjmed.2022.08.019

Ejemplares similares